Here are the 10-K annual reports from Quantum Genesis AI Corp (QGAI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow QGAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QGAI filings page.
Quantumzyme Corp. filed Amendment No. 2 to its annual report to update the Business, Risk Factors, and Certain Relationships sections, mainly to clarify ownership of key intellectual property. The company’s enzyme-engineering patent application for ibuprofen production was filed in its CEO’s name, and a confirmatory assignment now formally transfers all rights to Quantumzyme without additional consideration.
The amendment states that no audited financial statements or MD&A have been changed. Quantumzyme remains an early-stage, pre-revenue biotransformation company focused on engineered enzymes for pharmaceutical and other sustainable applications, operating with one employee, limited capital, significant competition, and a dual-class share structure that concentrates voting power.